Kanako Matsuoka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kanako Matsuoka has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Yoshiyuki Kojima
Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan
14 shared publications- Soichiro Ogawa
Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan
13 shared publications Yuichi Sato
Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan
12 shared publications- Junya Hata
Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan
10 shared publications Hidenori Akaihata
Department of Urology Fukushima Medical University School of Medicine Fukushima Japan
9 shared publications- Satoru Meguro
Department of Urology Fukushima Medical University School of Medicine Fukushima Japan
9 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 331 (5) , C1495-C1505
Piezo1 activation by Yoda1 inhibits mechanosensitive ATP release in human urothelial cells and bladder overactivity in rats with bladder outlet obstruction
Pharmacological activation of Piezo1 by Yoda1 suppresses mechanosensitive urothelial ATP release through Ca 2+ -dependent connexin hemichannel closure and Ca 2+ -independent mechanisms. In BOO rats, intravesical Yoda1 reduces elevated ATP levels and attenuates bladder overactivity without impairing voiding function, identifying Piezo1 as a novel therapeutic target for BOO-induced lower urinary tract dysfunction.
- 1 November 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 331 (5) , C1495-C1505
Open AccessPiezo1 activation by Yoda1 inhibits mechanosensitive ATP release in human urothelial cells and bladder overactivity in rats with bladder outlet obstruction
Pharmacological activation of Piezo1 by Yoda1 suppresses mechanosensitive urothelial ATP release through Ca 2+ -dependent connexin hemichannel closure and Ca 2+ -independent mechanisms. In BOO rats, intravesical Yoda1 reduces elevated ATP levels and attenuates bladder overactivity without impairing voiding function, identifying Piezo1 as a novel therapeutic target for BOO-induced lower urinary tract dysfunction.
- 23 October 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (10)
Maternal Parenting Styles and Nighttime Diaper Use in Early Childhood: The Japan Environment and Children's Study
Purpose: To examine cross‐sectional and longitudinal associations between maternal parenting style and nighttime diaper use in early childhood. Methods: We analyzed data from the Japan Environment and Children's Study, a nationwide prospective birth cohort. Maternal parenting styles were categorized as Authoritative, Authoritarian, Permissive, or Uninvolved using responsiveness and demandingness scores from a validated parenting attitude questionnaire. Nighttime diaper use was assessed at ages 3 and 4 years. Multivariable modified Poisson regression with robust error variance was applied to estimate adjusted prevalence ratios (aPRs) for nighttime diaper use at age 3 and adjusted risk ratios (aRRs) for its persistence from ages 3 to 4. Results: The cross‐sectional and longitudinal analyses included 65 765 and 54 915 mother–child pairs, respectively. Compared with the Uninvolved style, aPRs for nighttime diaper use at age 3 were 0.96 (95% CI, 0.95–0.97) for Authoritative, 0.99 (95% CI, 0.98–1.00) for Authoritarian, and 0.99 (95% CI, 0.99–1.00) for Permissive styles. The corresponding aRRs for persistent nighttime diaper use were 0.93 (95% CI, 0.91–0.95), 0.96 (95% CI, 0.94–0.98), and 0.98 (95% CI, 0.96–1.01). No significant interaction was found with child sex, whereas a significant interaction was observed between child developmental status and Authoritarian style. Conclusions: Maternal parenting styles were associated with nighttime diaper use at age 3 and its persistence at age 4. Although nighttime diaper use is not a direct measure of nocturnal continence, these findings suggest that maternal caregiving context may be relevant to early nighttime diaper discontinuation before school age. Trial Registration: ClinicalTrials.gov identifier: UMIN000030786
- 23 October 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (10)
Maternal Parenting Styles and Nighttime Diaper Use in Early Childhood: The Japan Environment and Children's Study
Purpose: To examine cross‐sectional and longitudinal associations between maternal parenting style and nighttime diaper use in early childhood. Methods: We analyzed data from the Japan Environment and Children's Study, a nationwide prospective birth cohort. Maternal parenting styles were categorized as Authoritative, Authoritarian, Permissive, or Uninvolved using responsiveness and demandingness scores from a validated parenting attitude questionnaire. Nighttime diaper use was assessed at ages 3 and 4 years. Multivariable modified Poisson regression with robust error variance was applied to estimate adjusted prevalence ratios (aPRs) for nighttime diaper use at age 3 and adjusted risk ratios (aRRs) for its persistence from ages 3 to 4. Results: The cross‐sectional and longitudinal analyses included 65 765 and 54 915 mother–child pairs, respectively. Compared with the Uninvolved style, aPRs for nighttime diaper use at age 3 were 0.96 (95% CI, 0.95–0.97) for Authoritative, 0.99 (95% CI, 0.98–1.00) for Authoritarian, and 0.99 (95% CI, 0.99–1.00) for Permissive styles. The corresponding aRRs for persistent nighttime diaper use were 0.93 (95% CI, 0.91–0.95), 0.96 (95% CI, 0.94–0.98), and 0.98 (95% CI, 0.96–1.01). No significant interaction was found with child sex, whereas a significant interaction was observed between child developmental status and Authoritarian style. Conclusions: Maternal parenting styles were associated with nighttime diaper use at age 3 and its persistence at age 4. Although nighttime diaper use is not a direct measure of nocturnal continence, these findings suggest that maternal caregiving context may be relevant to early nighttime diaper discontinuation before school age. Trial Registration: ClinicalTrials.gov identifier: UMIN000030786
- Open Access
- 30 September 2026
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 30 (3) , 233-242
Impact of Electrical Spinal Cord Stimulation on Lower Urinary Tract Dysfunction in Mice With Spinal Cord Injury
Purpose: We aimed to assess the effects of electrical stimulation of the L3–4 spinal cord containing the lumbar spinal coordinating center (LSCC) for neurogenic lower urinary tract dysfunction (NLUTD) in mice with spinal cord injury (SCI).Methods: Male mice were divided into spinal cord intact (SI) and SCI groups. Two electrodes were placed over the epidural surface of the L3–4 spinal cord for electrical spinal cord stimulation (SCS). SCS was initiated when the intravesical pressure of voiding bladder contractions began rising. Cystometrograms (CMG) and external urethral sphincter (EUS)-electromyography (EMG) were recorded before, during and after SCS to examine the effects of SCS on CMG and EUS-EMG parameters in each group.Results: In SI mice, significant differences in CMG parameters were not found after SCS compared to pre-SCS values. However, in SCI mice, the ratio of the voided volume to bladder filling volume was significantly higher after SCS compared to pre- SCS values (P<0.001). Additionally, SCI mice after SCS showed a significantly lower nonvoiding contraction number (P=0.017) and a shorter intercontraction interval (P=0.007) compared to those without SCS. EUS-EMG parameters in SI mice without and with SCS showed no significant differences in the ratio of active phases (AP) to silent phases (SP). In contrast, SCI mice with SCS had a significantly lower AP to SP ratio compared to those without SCS (P<0.001).Conclusions: SCS applied to the L3–4 spinal cord can improve detrusor sphincter dyssynergia by increasing EUS relaxation to mitigate inefficient voiding as well as detrusor overactivity in SCI. Restoration of the LSCC function by SCS could be a therapeutic modality to improve NLUTD after SCI.
- 30 September 2026
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 30 (3) , 233-242
Open AccessImpact of Electrical Spinal Cord Stimulation on Lower Urinary Tract Dysfunction in Mice With Spinal Cord Injury
Purpose: We aimed to assess the effects of electrical stimulation of the L3–4 spinal cord containing the lumbar spinal coordinating center (LSCC) for neurogenic lower urinary tract dysfunction (NLUTD) in mice with spinal cord injury (SCI).Methods: Male mice were divided into spinal cord intact (SI) and SCI groups. Two electrodes were placed over the epidural surface of the L3–4 spinal cord for electrical spinal cord stimulation (SCS). SCS was initiated when the intravesical pressure of voiding bladder contractions began rising. Cystometrograms (CMG) and external urethral sphincter (EUS)-electromyography (EMG) were recorded before, during and after SCS to examine the effects of SCS on CMG and EUS-EMG parameters in each group.Results: In SI mice, significant differences in CMG parameters were not found after SCS compared to pre-SCS values. However, in SCI mice, the ratio of the voided volume to bladder filling volume was significantly higher after SCS compared to pre- SCS values (P<0.001). Additionally, SCI mice after SCS showed a significantly lower nonvoiding contraction number (P=0.017) and a shorter intercontraction interval (P=0.007) compared to those without SCS. EUS-EMG parameters in SI mice without and with SCS showed no significant differences in the ratio of active phases (AP) to silent phases (SP). In contrast, SCI mice with SCS had a significantly lower AP to SP ratio compared to those without SCS (P<0.001).Conclusions: SCS applied to the L3–4 spinal cord can improve detrusor sphincter dyssynergia by increasing EUS relaxation to mitigate inefficient voiding as well as detrusor overactivity in SCI. Restoration of the LSCC function by SCS could be a therapeutic modality to improve NLUTD after SCI.
- Open Access
- 31 August 2026
- Published by Wiley in Neurourology and Urodynamics
Functional Roles of Adenosine A 2B and A 3 Receptor Subtypes in the Bladder of Male Rats With A 2B Receptor Deletion or Bladder Outlet Obstruction
Purpose: To investigate the adenosine receptor (AR) mechanism underlying bladder outlet obstruction (BOO)‐related bladder dysfunction, we examined the expression level of AR subtypes in bladder tissues, and the effects of AR subtypes A2B & A3 modulation on bladder activity using male BOO rats, and Dahl rats with A2B receptor deletion. Materials and Methods: BOO was induced by partial ligation of the proximal urethra in male Sprague‐Dawley rats. At 4 weeks after BOO, conscious cystometrograms (CMG) were performed with the urethral ligature being intact. The effects of AR A3 agonist (2CL‐IB‐MECA) and AR A3 antagonist (MRS3777) were examined by intravesical administration. Furthermore, we examined the difference of bladder function of AR subtypes between AR A2B knockout (A2B‐KO) and wild‐type groups of male Dahl rats. mRNA levels of AR subtypes in bladder tissues were also analyzed. Results: BOO versus sham rats showed heavier bladder weights, higher contraction amplitudes, and increased numbers of non‐voiding contractions (NVCs) during the filling phase. In the bladder mucosa – but not the detrusor ‐ of BOO versus sham rats, mRNA expression levels of A2A and A3 AR were significantly increased, while A2B levels were significantly decreased. In BOO rats, an A3 antagonist (MRS 3777; 10 and 100 μM) had no effect on CMG parameters. However, a high dose of an A3 agonist (2CL‐IB‐MECA; 100 μM) significantly increased NVCs ( p = 0.0034), an effect that was blocked by the A3 antagonist. Additionally, compared to wild‐type rats, A2B‐KO rats showed a significant increase in the number of NVCs ( p = 0.0039). Conclusions: A2B AR down‐regulation in BOO rats and A2B deletion in Dahl rats could contribute to the development of bladder overactivity. Moreover, a high‐level of exogenous activation of A3 ARs might exacerbate bladder overactivity in BOO.
- 31 August 2026
- Published by Wiley in Neurourology and Urodynamics
Open AccessFunctional Roles of Adenosine A 2B and A 3 Receptor Subtypes in the Bladder of Male Rats With A 2B Receptor Deletion or Bladder Outlet Obstruction
Purpose: To investigate the adenosine receptor (AR) mechanism underlying bladder outlet obstruction (BOO)‐related bladder dysfunction, we examined the expression level of AR subtypes in bladder tissues, and the effects of AR subtypes A2B & A3 modulation on bladder activity using male BOO rats, and Dahl rats with A2B receptor deletion. Materials and Methods: BOO was induced by partial ligation of the proximal urethra in male Sprague‐Dawley rats. At 4 weeks after BOO, conscious cystometrograms (CMG) were performed with the urethral ligature being intact. The effects of AR A3 agonist (2CL‐IB‐MECA) and AR A3 antagonist (MRS3777) were examined by intravesical administration. Furthermore, we examined the difference of bladder function of AR subtypes between AR A2B knockout (A2B‐KO) and wild‐type groups of male Dahl rats. mRNA levels of AR subtypes in bladder tissues were also analyzed. Results: BOO versus sham rats showed heavier bladder weights, higher contraction amplitudes, and increased numbers of non‐voiding contractions (NVCs) during the filling phase. In the bladder mucosa – but not the detrusor ‐ of BOO versus sham rats, mRNA expression levels of A2A and A3 AR were significantly increased, while A2B levels were significantly decreased. In BOO rats, an A3 antagonist (MRS 3777; 10 and 100 μM) had no effect on CMG parameters. However, a high dose of an A3 agonist (2CL‐IB‐MECA; 100 μM) significantly increased NVCs ( p = 0.0034), an effect that was blocked by the A3 antagonist. Additionally, compared to wild‐type rats, A2B‐KO rats showed a significant increase in the number of NVCs ( p = 0.0039). Conclusions: A2B AR down‐regulation in BOO rats and A2B deletion in Dahl rats could contribute to the development of bladder overactivity. Moreover, a high‐level of exogenous activation of A3 ARs might exacerbate bladder overactivity in BOO.
- 1 May 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 330 (5) , F592-F600
Therapeutic effects of imidazoline 2 receptor activation on lower urinary tract dysfunction in a mouse model of spinal cord injury
This study shows that selective activation of the imidazoline-2 receptor improves both detrusor overactivity and detrusor-sphincter dyssynergia after spinal cord injury. Systemic and intrathecal administration of 2BFI produced coordinated actions in the spinal cord and lower urinary tract, including enhanced relaxation of the external urethral sphincter, reduced inflammation mediated by C-fiber afferents, and direct relaxation of bladder smooth muscle, indicating a promising therapeutic target.
- 1 May 2026
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 330 (5) , F592-F600
Therapeutic effects of imidazoline 2 receptor activation on lower urinary tract dysfunction in a mouse model of spinal cord injury
This study shows that selective activation of the imidazoline-2 receptor improves both detrusor overactivity and detrusor-sphincter dyssynergia after spinal cord injury. Systemic and intrathecal administration of 2BFI produced coordinated actions in the spinal cord and lower urinary tract, including enhanced relaxation of the external urethral sphincter, reduced inflammation mediated by C-fiber afferents, and direct relaxation of bladder smooth muscle, indicating a promising therapeutic target.
- Open Access
Immunosuppressive Role of Integrin β8 in Recurrence After Bacillus Calmette–Guérin (BCG) Therapy for Non-Muscle Invasive Bladder Cancer
Background: Although immunosuppressive factors contribute to the recurrence of non-muscle invasive bladder cancer (NMIBC) during Bacillus Calmette–Guérin (BCG) therapy, the mechanism remains unclear. Methods: In this study, key players in the immunosuppression associated with recurrence after BCG therapy were identified through comprehensive genetic and functional analyses of untreated NMIBC. Results: Microarray analysis of bladder cancer tissue from 13 eligible NMIBC patients revealed an association between high expression of integrin β8 (ITGB8) and recurrence after BCG treatment (p < 0.001). In UMUC cells exhibiting high ITGB8 expression, ITGB8 knockdown significantly decreased cell growth, invasion, adhesion, and secretion of the immunosuppressive cytokine transforming growth factor-β1 (TGF-β1, p < 0.01 for each). In addition, ITGB8 and TGF-β1 expression were correlated in immunohistochemistry of surgical specimens from 13 patients (p < 0.05). These results indicate that ITGB8 regulates TGF-β1 secretion. Conclusions: ITGB8 may contribute to post-BCG therapy recurrence of NMIBC by suppressing tumor immunity through the activation of TGF-β1. Evaluation of ITGB8 expression in preoperative NMIBC could potentially predict recurrence following intravesical BCG therapy.
Open AccessImmunosuppressive Role of Integrin β8 in Recurrence After Bacillus Calmette–Guérin (BCG) Therapy for Non-Muscle Invasive Bladder Cancer
Background: Although immunosuppressive factors contribute to the recurrence of non-muscle invasive bladder cancer (NMIBC) during Bacillus Calmette–Guérin (BCG) therapy, the mechanism remains unclear. Methods: In this study, key players in the immunosuppression associated with recurrence after BCG therapy were identified through comprehensive genetic and functional analyses of untreated NMIBC. Results: Microarray analysis of bladder cancer tissue from 13 eligible NMIBC patients revealed an association between high expression of integrin β8 (ITGB8) and recurrence after BCG treatment (p < 0.001). In UMUC cells exhibiting high ITGB8 expression, ITGB8 knockdown significantly decreased cell growth, invasion, adhesion, and secretion of the immunosuppressive cytokine transforming growth factor-β1 (TGF-β1, p < 0.01 for each). In addition, ITGB8 and TGF-β1 expression were correlated in immunohistochemistry of surgical specimens from 13 patients (p < 0.05). These results indicate that ITGB8 regulates TGF-β1 secretion. Conclusions: ITGB8 may contribute to post-BCG therapy recurrence of NMIBC by suppressing tumor immunity through the activation of TGF-β1. Evaluation of ITGB8 expression in preoperative NMIBC could potentially predict recurrence following intravesical BCG therapy.
- 30 September 2025
- Published by Wiley in International Journal of Urology
- Vol. 33 (1)
Abdominal Subcutaneous Fat Thickness Is a Useful Predictor for Lower Urinary Tract Dysfunction After Robot‐Assisted Radical Prostatectomy
Objective: Obesity is known to be an important patient‐related factor in predicting lower urinary tract dysfunction (LUTD) after robot‐assisted radical prostatectomy (RARP). The present study aimed to investigate the usefulness of subcutaneous and visceral fat thickness as measures of obesity in predicting LUTD after RARP. Materials and Methods: A total of 536 patients who had undergone RARP at our institution were included in the study. We measured the abdominal subcutaneous fat thickness (SCFT) and periprostatic fat thickness (PPFT) on preoperative magnetic resonance imaging as indicators of subcutaneous and visceral fat, respectively. Uroflowmetry and a one‐hour pad test were performed in all patients at 1, 3, 6, and 12 months after RARP, and the resulting data were used to calculate bladder voiding efficiency (BVE) and the amount of urinary leakage as objective postoperative parameters. Associations between preoperative SCFT or PPFT and these parameters were evaluated using univariate and multivariate regression analyses. Results: In the univariate analysis, SCFT was significantly correlated with BVE at 1, 3, 6, and 12 months ( p < 0.05), and with the amount of urinary leakage at 3, 6, and 12 months ( p < 0.05). In the multivariate analysis, SCFT was significantly associated with BVE at 1, 3, 6, and 12 months ( p < 0.05), as well as the amount of urinary leakage at 3, 6, and 12 months ( p < 0.05). Conclusion: High SCFT was significantly associated with a low BVE and increased urinary incontinence after RARP. SCFT may be a useful predictor of LUTD.
- 30 September 2025
- Published by Wiley in International Journal of Urology
- Vol. 33 (1)
Abdominal Subcutaneous Fat Thickness Is a Useful Predictor for Lower Urinary Tract Dysfunction After Robot‐Assisted Radical Prostatectomy
Objective: Obesity is known to be an important patient‐related factor in predicting lower urinary tract dysfunction (LUTD) after robot‐assisted radical prostatectomy (RARP). The present study aimed to investigate the usefulness of subcutaneous and visceral fat thickness as measures of obesity in predicting LUTD after RARP. Materials and Methods: A total of 536 patients who had undergone RARP at our institution were included in the study. We measured the abdominal subcutaneous fat thickness (SCFT) and periprostatic fat thickness (PPFT) on preoperative magnetic resonance imaging as indicators of subcutaneous and visceral fat, respectively. Uroflowmetry and a one‐hour pad test were performed in all patients at 1, 3, 6, and 12 months after RARP, and the resulting data were used to calculate bladder voiding efficiency (BVE) and the amount of urinary leakage as objective postoperative parameters. Associations between preoperative SCFT or PPFT and these parameters were evaluated using univariate and multivariate regression analyses. Results: In the univariate analysis, SCFT was significantly correlated with BVE at 1, 3, 6, and 12 months ( p < 0.05), and with the amount of urinary leakage at 3, 6, and 12 months ( p < 0.05). In the multivariate analysis, SCFT was significantly associated with BVE at 1, 3, 6, and 12 months ( p < 0.05), as well as the amount of urinary leakage at 3, 6, and 12 months ( p < 0.05). Conclusion: High SCFT was significantly associated with a low BVE and increased urinary incontinence after RARP. SCFT may be a useful predictor of LUTD.
- Open Access
- 18 August 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (8) , 467
Targeting Senescence in Oncology: An Emerging Therapeutic Avenue for Cancer
Since cancer is often linked to the aging process, the importance of cellular senescence in cancer has come under the spotlight. While senescence in cancer cells can serve as a natural barrier against cancer due to its proliferation arrest, its secretory phenotypes and alterations in the surface proteome can paradoxically promote or suppress tumor progression. Senescent cancer-associated fibroblasts, endothelial cells, and immune cells can also contribute to cancer promotion. During therapeutic interventions for cancer, not only their therapeutic effects, but also therapy-induced senescence may have an impact on cancer outcomes. Senotherapeutics, therapy targeting senescent cells, have been reported as novel cancer therapy in recent studies, and the combination of senescence induction and senotherapeutics has been increasingly recognized. Although some clinical trials of senotherapeutic drugs for cancer with or without senescence-inducible therapy are ongoing, there is as yet no satisfactory clinical application. With further research into targeting senescence in oncology, it is expected that senotherapeutics, particularly in combination with senescence-inducing therapy, will become a novel therapeutic strategy.
- 18 August 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (8) , 467
Open AccessTargeting Senescence in Oncology: An Emerging Therapeutic Avenue for Cancer
Since cancer is often linked to the aging process, the importance of cellular senescence in cancer has come under the spotlight. While senescence in cancer cells can serve as a natural barrier against cancer due to its proliferation arrest, its secretory phenotypes and alterations in the surface proteome can paradoxically promote or suppress tumor progression. Senescent cancer-associated fibroblasts, endothelial cells, and immune cells can also contribute to cancer promotion. During therapeutic interventions for cancer, not only their therapeutic effects, but also therapy-induced senescence may have an impact on cancer outcomes. Senotherapeutics, therapy targeting senescent cells, have been reported as novel cancer therapy in recent studies, and the combination of senescence induction and senotherapeutics has been increasingly recognized. Although some clinical trials of senotherapeutic drugs for cancer with or without senescence-inducible therapy are ongoing, there is as yet no satisfactory clinical application. With further research into targeting senescence in oncology, it is expected that senotherapeutics, particularly in combination with senescence-inducing therapy, will become a novel therapeutic strategy.
- Open Access
- 3 June 2025
- Published by Wiley in IJU Case Reports
- Vol. 8 (4) , 427-430
Bilateral High Intra‐Abdominal Testes Successfully Treated With Multistage Fowler–Stephens Orchiopexy to Preserve Testicular Function
Introduction: A case of bilateral high intra‐abdominal testes successfully treated with multistage Fowler–Stephens orchiopexy is reported.Case Presentation: A 6‐month‐old boy with bilateral nonpalpable testes was diagnosed with a left intra‐abdominal testis located immediately caudal to the spleen on magnetic resonance imaging and laparoscopy. At the age of 4 years, diffusion‐weighted magnetic resonance imaging detected a structure immediately caudal to the liver, which was suspected to be the right testis. With a diagnosis of bilateral intra‐abdominal testes, one‐stage Fowler–Stephens orchiopexy was performed on the right testis at 5 years of age. After confirming its development, two‐stage Fowler–Stephens orchiopexy was performed on the left testis at 10 years of age.Conclusion: After confirming the development of the right testis that underwent one‐stage Fowler–Stephens orchiopexy, two‐stage Fowler–Stephens orchiopexy was completed on the left testis, resulting in the successful preservation of both testes and normal sexual development.
- 3 June 2025
- Published by Wiley in IJU Case Reports
- Vol. 8 (4) , 427-430
Open AccessBilateral High Intra‐Abdominal Testes Successfully Treated With Multistage Fowler–Stephens Orchiopexy to Preserve Testicular Function
Introduction: A case of bilateral high intra‐abdominal testes successfully treated with multistage Fowler–Stephens orchiopexy is reported.Case Presentation: A 6‐month‐old boy with bilateral nonpalpable testes was diagnosed with a left intra‐abdominal testis located immediately caudal to the spleen on magnetic resonance imaging and laparoscopy. At the age of 4 years, diffusion‐weighted magnetic resonance imaging detected a structure immediately caudal to the liver, which was suspected to be the right testis. With a diagnosis of bilateral intra‐abdominal testes, one‐stage Fowler–Stephens orchiopexy was performed on the right testis at 5 years of age. After confirming its development, two‐stage Fowler–Stephens orchiopexy was performed on the left testis at 10 years of age.Conclusion: After confirming the development of the right testis that underwent one‐stage Fowler–Stephens orchiopexy, two‐stage Fowler–Stephens orchiopexy was completed on the left testis, resulting in the successful preservation of both testes and normal sexual development.
- Open Access
- 28 May 2025
- Published by Wiley in IJU Case Reports
- Vol. 8 (4) , 419-422
Combination of Neoadjuvant Gemcitabine‐Cisplatin and Anti‐Tuberculosis Therapy for a Patient With Muscle‐Invasive Bladder Cancer and Renal Granulomatosis That Progressed After Intravesical Bacillus Calmette‐Guérin Therapy
Introduction: A case of muscle‐invasive bladder cancer and renal granulomatosis that developed after intravesical Bacillus Calmette‐Guérin therapy, in which a combination of neoadjuvant gemcitabine‐cisplatin and anti‐tuberculosis therapy was safely administered, and radical cystectomy was ultimately performed, is reported.Case Presentation: A 64‐year‐old man with non‐muscle‐invasive bladder cancer underwent transurethral resection and intravesical Bacillus Calmette‐Guérin therapy every time bladder cancer recurred. However, the patient developed left renal granulomatosis during treatment. Anti‐tuberculosis therapy was prioritized since there was no bladder cancer progression. However, local bladder cancer progression was observed during the anti‐tuberculosis therapy. To successfully cure the renal granulomatosis and suppress tumor progression, neoadjuvant gemcitabine‐cisplatin was combined with anti‐tuberculosis therapy for 2 months, followed by radical cystectomy. There were no gemcitabine‐cisplatin complications and no renal granulomatosis recurrence during combination therapy.Conclusion: Combination of gemcitabine‐cisplatin and anti‐tuberculosis therapy was possible for a patient with bladder cancer when Bacillus Calmette‐Guérin infection was under control.
- 28 May 2025
- Published by Wiley in IJU Case Reports
- Vol. 8 (4) , 419-422
Open AccessCombination of Neoadjuvant Gemcitabine‐Cisplatin and Anti‐Tuberculosis Therapy for a Patient With Muscle‐Invasive Bladder Cancer and Renal Granulomatosis That Progressed After Intravesical Bacillus Calmette‐Guérin Therapy
Introduction: A case of muscle‐invasive bladder cancer and renal granulomatosis that developed after intravesical Bacillus Calmette‐Guérin therapy, in which a combination of neoadjuvant gemcitabine‐cisplatin and anti‐tuberculosis therapy was safely administered, and radical cystectomy was ultimately performed, is reported.Case Presentation: A 64‐year‐old man with non‐muscle‐invasive bladder cancer underwent transurethral resection and intravesical Bacillus Calmette‐Guérin therapy every time bladder cancer recurred. However, the patient developed left renal granulomatosis during treatment. Anti‐tuberculosis therapy was prioritized since there was no bladder cancer progression. However, local bladder cancer progression was observed during the anti‐tuberculosis therapy. To successfully cure the renal granulomatosis and suppress tumor progression, neoadjuvant gemcitabine‐cisplatin was combined with anti‐tuberculosis therapy for 2 months, followed by radical cystectomy. There were no gemcitabine‐cisplatin complications and no renal granulomatosis recurrence during combination therapy.Conclusion: Combination of gemcitabine‐cisplatin and anti‐tuberculosis therapy was possible for a patient with bladder cancer when Bacillus Calmette‐Guérin infection was under control.